Pan-cancer landscape of DCTPP1 and preliminary exploration of DCTPP1 in renal clear cell carcinoma

Sep 21, 2026

Uploaded by Quinn

dCTPP1 is broadly expressed in tumors and the immune system and is linked to cancer progression, yet its pan-cancer characterization and clinical value remain unclear. This study compiles data from 33 cancers to analyze DCTPP1 expression patterns, prognostic impact, pathway enrichment, immune microenvironment associations, and drug-sensitivity links. It further predicts immunotherapy response to ICIs and targeted small molecules, and validates DCTPP1’s role experimentally in renal clear cell carcinoma, highlighting biomarker potential.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

Materials and methods

Data sources

Prognostic analysis

[www. nature.com/scientificreports](www. nature.com/scientificreports) OPEN Pan-cancer landscape of DCTPP1 and preliminary exploration of DCTPP1 in renal clear cell carcinoma Hongze Li1,4, Yan Xu1,4, Jingjing Shan2 & Yu Lun3􀀍 dCTP pyrophosphatase 1 (DCTPP1) is widely expressed in tumors and the immune system and plays a critical role in human cancer progression. However, multi-omics characterization of DCTPP1 and its role in prognosis and immune microenvironment of tumor patients has not been explored. We collected data from 33 cancers and comprehensively analyzed the aberrant expression, prognostic role, pathway enrichment, immune microenvironment, and association with drug sensitivity of DCTPP1 in cancers, as well as the prediction of patients’ immunotherapeutic response to ICIs and targeted small molecule drugs. Finally, we experimentally confirmed the role of DCTPP1 in renal clear cell carcinoma. We discovered that DCTPP1 has a differentiable expression and a diagnostic biomarker significance in cancer. Additionally, we discovered that DCTPP1 is important for the tumor microenvironment and pan-cancer. TMB and MSI are frequent immunological checkpoints that are significantly correlated with DCTPP1 expression. Patients who express high levels of DCTPP1 have greater rates of survival and therapeutic response following immunotherapy. Ultimately, it was discovered that renal clear cell carcinoma cells’ invasion and proliferation were suppressed by DCTPP1 knockdown. Our findings demonstrate the significant potential of DCTPP1 as a biomarker for prognosis and immunotherapeutic response, which may pave the way for more investigation into the mechanism of tumor infiltration and DCTPP1’s potential for cancer therapy. Keywords DCTPP1, Pan-cancer, Tumor microenvironment, Immunotherapy, Renal clear cell carcinoma The survival rate of cancer patients has increased in the last twenty years as a result of advancements in cancer treatment procedures1. The significance of the tumor microenvironment (TME) in the progression and management of human cancer is increasingly acknowledged2. Within the tumor microenvironment (TME), cancer cells frequently alter the typical levels of inflammatory cytokines and chemokines, which hampers the immune response and promotes tumor growth while hindering cancer treatment3,4. The significance of the tumor microenvironment in determining the efficacy of immunotherapy has been established5. Thus, investigating the function of new immunotherapeutic biomarkers in the tumor microenvironment may aid in the creation of more potent immunotherapy treatments for cancer patients and attain long-lasting immunotherapeutic outcomes. dCTP pyrophosphatase 1 (DCTPP1) is an enzyme that specifically catalyzes the hydrolysis of dCTP pyrophosphate. DCTPP1, in contrast to NTP-PPases, exhibits the ability to hydrolyze dCTP, 5-methylbasedCTP, and 5-halo-dCTP, while NTP-PPases are known to hydrolyze dGTP and dUTP and their derivatives6. DCTTP1 exhibits nuclear localization in several carcinomas, diminishes the responsiveness of human gastric cancer cells to 5-fluorouracil by epigenetically enhancing MDR1 expression, and plays a role in the cellular reaction to decitabine7,8. Nevertheless, the precise impact of DCTPP1 on the prognosis and immunological milieu of tumor patients, particularly those with clear cell renal cell carcinoma, remains mainly unexplored. This work utilized the TCGA and GTEx RNA-seq datasets to uncover abnormal mRNA and protein expression of DCTPP1 in pancreatic cancer in humans. The predictive relevance of DCTPP1 in various malignancies was assessed using one-way Cox regression and Kaplan-Meier curves. Additionally, Hallmark gene set enrichment analysis was employed to identify cancer marker pathways that are linked to DCTPP1 expression. Diverse software outcomes were employed to unveil the association between DCTPP1 and the invasion of immune cells. 1Department of Urology, The First Hospital

FAQs

What question does the study address about DCTPP1?

The study investigates how DCTPP1 is characterized across many cancers and how it relates to prognosis and the tumor immune microenvironment, including response to immunotherapy and targeted drugs.

What datasets and resources are used to analyze DCTPP1?

The work uses TCGA and GTEx RNA-seq data, evaluates differential expression via GEPIA, obtains protein data from CPTAC, and includes immune checkpoint blockade datasets IMvigor210 and GSE100797.

How is the role of DCTPP1 examined in renal clear cell carcinoma?

The study experimentally confirms that suppressing DCTPP1 expression inhibits invasion and proliferation of renal clear cell carcinoma cells and supports DCTPP1 as a potential therapeutic target and biomarker.

Sep 21, 2026

Uploaded by Quinn